Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Armata Pharmaceuticals, Inc. (ARMP) is a Biotechnology company based in US with a market capitalization of $189.4M. Revenue declined 5.2% year-over-year and free cash flow was negative at -$26.3M. This page tracks ARMP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 60 employees · IPO May 20, 1994
Valuation
Valuation & price
$8.05as of May 17, 2026· -45.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
—
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$189.4M
Market cap
-5.2%
Revenue growth (YoY)
68.8%
Gross margin
-$26.3M
Free cash flow (USD)
$279.3M
Net debt
0.2%
Share dilution
0/4
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 20, 2026Filing
CFO Employment Agreement
- 8-K eventJul 20, 2026Filing
Clinical Progress Announcement
- 8-K eventJul 13, 2026Filing
FDA Agreement on Pediatric Study
- 8-K eventJun 24, 2026Filing
Board Committee Assignment
- 8-K eventJun 23, 2026Filing
Funding Award Received
- 8-K eventJun 16, 2026Filing
Annual Shareholder Meeting
- 8-K eventMay 13, 2026Filing
Credit Agreement Executed
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
FDA Fast Track Designation
- 8-K eventApr 27, 2026Filing
Director Appointment
Questions
Frequently asked questions
What is Armata Pharmaceuticals, Inc.'s market cap?
Armata Pharmaceuticals, Inc. (ARMP) has a market capitalization of $189.4M.
What is ARMP's P/E ratio?
A meaningful P/E ratio is not available for ARMP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
Are insiders buying ARMP stock?
SEC Form 4 filings show no open-market insider buys at Armata Pharmaceuticals, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.